CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete.

Partial results indicate that at selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in BP relative to placebo, with volunteers averaging a notable reduction of 7.0% (p<0.001) in systolic pressure. In addition, over the same period, volunteers averaged a significant reduction of 5.3% (p<0.001) in MAP and a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure (-0.8 vs. +2.7; p<0.001) from baseline with DehydraTECH-CBD relative to placebo treatment. The company noted that these numbers are particularly remarkable because many drugs currently used to treat hypertension require several weeks of treatment and/or combination dosing before they produce comparable results.

Moving forward, Lexaria will evaluate the results of its first two human clinical hypertension studies before its upcoming pulmonary human clinical hypertension study of begins. “Over the initial 24 hours, Lexaria’s 2021 …

Full story available on Benzinga.com

More CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction